Mammary Cell News Volume 4.15 | Apr 19 2012

LABORATORY RESEARCH

Polycomb Protein EZH2 Regulates Tumor Invasion via the Transcriptional Repression of the Metastasis Suppressor RKIP in Breast and Prostate Cancer
Scientists show that the RKIP/EZH2 ratio significantly decreases with the severity of disease and is negatively associated with relapse-free survival in breast cancer. [Cancer Res] Abstract

Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer
Researchers analyzed paired-end mRNA-Seq data from a panel of estrogen receptor-positive, HER2⁺, and triple-negative primary breast tumors. [Cancer Res] Abstract | Press Release

Re-Expression of MicroRNA-375 Reverses Both Tamoxifen Resistance and Accompanying EMT-Like Properties in Breast Cancer
To investigate the role of microRNAs in the development of resistance to tamoxifen as well as accompanying epithelial-mesenchymal transition (EMT)-like properties, researchers established a tamoxifen-resistant model by continually exposing MCF-7 breast cancer cells to tamoxifen. [Oncogene] Abstract

Specific β-Containing Integrins Exert Differential Control on Proliferation and Two-Dimensional Collective Cell Migration in Mammary Epithelial Cells
Researchers described the consequences of removing the β1-integrin gene from primary cultures of mammary epithelial cells in situ, using CreER. [J Biol Chem] Abstract

X-Linked Inhibitor of Apoptosis Protein Inhibition and Generation of Reactive Oxygen Species Enhances TRAIL Sensitivity in Inflammatory Breast Cancer Cells
Researchers evaluated the effect of classical apoptosis inducing agent TRAIL in an inflammatory breast cancer acquired resistance model. [Mol Cancer Ther] Abstract

BRCA1-IRIS Overexpression Promotes Formation of Aggressive Breast Cancers
Investigators examined whether BRCA1-IRIS is a valuable treatment target for HER2⁺ and/or triple negative/basal-like tumors. [PLoS One] Abstract

Human Amniotic Fluid-Derived Stem Cells Expressing Cytosine Deaminase and Thymidine Kinase Inhibits the Growth of Breast Cancer Cells in Cellular and Xenograft Mouse Models
Researchers used human amniotic fluid-derived stem cells as vehicles for targeted delivery of therapeutic suicide genes to breast cancer cells. [Cancer Gene Ther] Abstract

Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2+ Breast Cancer Growth and Metastasis
Scientists tested whether Polo-like kinase 1 (PLK1) small interfering RNAs (siRNAs) complexed with a Her2-single-chain fragmented antibody (ScFv)-protamine peptide fusion protein could suppress Her2⁺ breast cancer cell lines and primary human cancers in orthotopic breast cancer models. [Sci Transl Med]
Abstract | Press Release

CLINICAL RESEARCH

Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients
Scientists determined whether high affinity single nucleotide polymorphisms are associated with disease free survival among patients with HER2-positive non-metastatic breast cancer. [Clin Cancer Res] Abstract

Breast Cancer Incidence in Postmenopausal Women with Osteoporosis or Low Bone Mass Using Arzoxifene
Investigators report breast cancer findings from the Generations trial, a multicenter, placebo-controlled, double-blind trial, that compared arzoxifene 20 mg/day and placebo in 9,354 postmenopausal women with osteoporosis or low bone mass. [Breast Cancer Res Treat] Abstract

Novian Health Begins Breast Cancer Clinical Trial
Novian Health announced the company has begun a multicenter clinical trial on the use of Novilase^® Interstitial Laser Therapy for the destruction of malignant breast tumors. [Novian Health] Press Release

Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145)
Merck and Endocyte Inc. announced that they have entered into an agreement to develop and commercialize Endocyte’s novel investigational therapeutic candidate EC145. [Merck Sharp & Dohme Corp.] Press Release

NEW European Association for Cancer Research (EACR)-22: From Basic Research to Personalized Cancer Treatment
July 7-10, 2012
Barcelona, Spain

Visit our events page to see a complete list of events in the mammary cell community.

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Hematology (STEMCELL Technologies, Inc.)

Scientist – hPSC (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Postdoctoral Position – Breast Cancer/Stem Cell Biology (University of Cincinnati – College of Medicine)

Postdoctoral Research Fellow (Cancer Research UK – Cambridge Research Institute) 

Post-Doctoral Position – Translational Breast Cancer Research (ISREC/EPFL)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Middle East to Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.